发布求助
文献互助 智能选刊 最新文献

Im Focus Onkologie最新文献

筛选
英文 中文
Prognostiziertes Marktpotenzial weckt Fantasie bei Anlegern 展望市场潜力让投资者很聪明
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4380-5
Hauke Gerlof
{"title":"Prognostiziertes Marktpotenzial weckt Fantasie bei Anlegern","authors":"Hauke Gerlof","doi":"10.1007/s15015-018-4380-5","DOIUrl":"https://doi.org/10.1007/s15015-018-4380-5","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"1 1","pages":"74-75"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83172769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trotz Konisation erhöhtes Zervixkarzinomrisiko nach CIN3 只要是有…一半被感染的病患
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4354-7
Kathrin von Kieseritzky
{"title":"Trotz Konisation erhöhtes Zervixkarzinomrisiko nach CIN3","authors":"Kathrin von Kieseritzky","doi":"10.1007/s15015-018-4354-7","DOIUrl":"https://doi.org/10.1007/s15015-018-4354-7","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"93 1","pages":"38"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83343804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fortgeschrittenes platinsensitives Ovarialkarzinom: Niraparib wirksam in allen Subgruppen
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4308-0
A. Bischoff
{"title":"Fortgeschrittenes platinsensitives Ovarialkarzinom: Niraparib wirksam in allen Subgruppen","authors":"A. Bischoff","doi":"10.1007/s15015-018-4308-0","DOIUrl":"https://doi.org/10.1007/s15015-018-4308-0","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"89 1","pages":"73 - 73"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73450441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Videosprechstunde — Patienten wollen, Ärzte warten noch
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4305-3
Hauke Gerlof
{"title":"Videosprechstunde — Patienten wollen, Ärzte warten noch","authors":"Hauke Gerlof","doi":"10.1007/s15015-018-4305-3","DOIUrl":"https://doi.org/10.1007/s15015-018-4305-3","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"63 1","pages":"72"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78756272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metastasiertes Melanom: Ältere sprechen besser auf Checkpointhemmer an 转移的黑素:老的会很容易使用检查站底
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4291-5
Peter Leiner
{"title":"Metastasiertes Melanom: Ältere sprechen besser auf Checkpointhemmer an","authors":"Peter Leiner","doi":"10.1007/s15015-018-4291-5","DOIUrl":"https://doi.org/10.1007/s15015-018-4291-5","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"44 1","pages":"49"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88374065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SCLC: Erster Lichtblick nach zwei Jahrzehnten des Stillstands 南方基督教领袖会议二次会议
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4309-z
Red.
{"title":"SCLC: Erster Lichtblick nach zwei Jahrzehnten des Stillstands","authors":"Red.","doi":"10.1007/s15015-018-4309-z","DOIUrl":"https://doi.org/10.1007/s15015-018-4309-z","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"68 1","pages":"74 - 74"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91264664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PARP-Inhibition beim fortgeschrittenen Ovarialkarzinom 高级卵巢癌的parl抑制剂
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4287-1
A. Bischoff
{"title":"PARP-Inhibition beim fortgeschrittenen Ovarialkarzinom","authors":"A. Bischoff","doi":"10.1007/s15015-018-4287-1","DOIUrl":"https://doi.org/10.1007/s15015-018-4287-1","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"11 1","pages":"45-46"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78547170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rektumkarzinom: NAR-Score hilft bei Therapieentscheidungen 直肠癌，纳尔蝎子帮你做出抉择
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4275-5
J. Neumaier
{"title":"Rektumkarzinom: NAR-Score hilft bei Therapieentscheidungen","authors":"J. Neumaier","doi":"10.1007/s15015-018-4275-5","DOIUrl":"https://doi.org/10.1007/s15015-018-4275-5","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"17 1","pages":"35"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74391179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Orale Onkologika: Risiko für Wechselwirkungen bedenken 口腔肿瘤学:存在相互作用的风险
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4273-7
Silke Wedekind
{"title":"Orale Onkologika: Risiko für Wechselwirkungen bedenken","authors":"Silke Wedekind","doi":"10.1007/s15015-018-4273-7","DOIUrl":"https://doi.org/10.1007/s15015-018-4273-7","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"148 1","pages":"32-34"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80652758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CLL: Immunphänotypisierung des Liquors unumgänglich bei neurologischen Symptomen CLL，免疫表型
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4294-2
Robert Bublak
{"title":"CLL: Immunphänotypisierung des Liquors unumgänglich bei neurologischen Symptomen","authors":"Robert Bublak","doi":"10.1007/s15015-018-4294-2","DOIUrl":"https://doi.org/10.1007/s15015-018-4294-2","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"3 1","pages":"50"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83101775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信